Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.66 | N/A | +7.58% |
management commentary, guidance changes, and full analysis available with Pro.
| +7.58% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
This earnings report shows that Johnson & Johnson performed better than expected in terms of EPS, indicating strong profitability. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, but the positive EPS surprise suggests some confidence in the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GOLDMAN SACHS GROUP
Jul 15, 2014